Latest Breaking News On - Azura ophthalmics - Page 1 : comparemela.com

ViaNautis Bio appoints Dr Steven M Altschuler as Chairman of its Board of Directors

ViaNautis Bio appoints Dr Steven M Altschuler as Chairman of its Board of Directors
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesStevenm altschulerFrancesca crawfordFran crawfordEli lillyOwen smithVianautis bioAmber fennellNamrata taakCase western reserve universityDrug administrationCorner therapeutics incEuropean medicines agencyNautis bioSpark therapeuticsUnited kingdom

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Study met its primary endpoint and showed significant and clinically meaningful improvements in multiple symptoms of Contact Lens Discomfort and signs of concomitant Meibomian Gland Dysfunction

United statesLyndon jonesAshwin agarwalJenna kaneMarc gleesonInternational workshop on contact lens discomfortResearch future fundAmerican optometric associationAzura primary researchCentre for ocular research education in ontarioAzura ophthalmics ltdContact lens discomfortMeibomian glandOphthalmic keratolyticsMeibomian gland dysfunctionMeibomian glands yielding liquid secretion

DelveInsight Business Research, LLP: DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain

The prevalence of dry eye disease has been rising over the past few years, which prompts the growing demand for treatment options. The increasing prevalence of dry eye disease and the growing

United statesNovaliq gmbShruti thakurGewinn nurHanall biopharmaPrnewswire delveinsightHuons co ltdBiotechnology incAxerovision incAldeyra therapeutics incAerie pharmaceuticalsNovartis pharmaceuticalsGlaukos corporationAbbvie incAllergan plcInvirsa inc

DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain

/PRNewswire/ DelveInsight s Dry Eye Disease Pipeline Insight – 2023 report provides comprehensive global coverage of pipeline dry eye disease therapies in.

United statesPrnewswire delveinsightHanall biopharmaShruti thakurNovaliq gmbKey companiesUniversity collaborations licensing partnering analysisYuyu pharma incAerie pharmaceuticals incSelagine incEuropean medicines agencyMarket researchAssociation for researchLomb corporationBausch health companies incAxerovision inc

Azura Ophthalmics to Present New Data on AZR-MD-001 in Meibomian Gland Dysfunction at American Socie

Robust safety and efficacy data supports advancing AZR-MD-001 into Phase 3 clinical trials TEL AVIV, Israel (BUSINESS WIRE) Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple pre.

San diegoUnited statesLisam nijmJenna kaneLimor miaraMarc gleesonFiona stapletonJenniferp craigPreeyak guptaUniversity of illinois eye ear infirmaryUniversity of south wales medicine healthMeetings for the association researchTulane universityAzura ophthalmics ltdAmerican society of cataractOphthalmic keratolytics